Home > Boards > US Listed > Biotechs > Agenus (AGEN)

The Facts About PD-1 according to Feb.25 newsletter.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
dia76ca Member Profile
 
Followed By 50
Posts 5,395
Boards Moderated 1
Alias Born 12/13/04
160x600 placeholder
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 GlobeNewswire Inc. - 7/7/2021 4:05:00 PM
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibod... GlobeNewswire Inc. - 7/6/2021 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 7:34:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 7:32:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 6:01:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 6:01:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 6:00:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 5:58:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 5:57:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/21/2021 6:58:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/21/2021 5:14:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/21/2021 5:02:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/21/2021 4:58:22 PM
Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference GlobeNewswire Inc. - 6/21/2021 9:00:00 AM
FDA accepts Agenus' balstilimab BLA under "priority review" status Seeking Alpha - 6/17/2021 8:45:02 AM
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Re... GlobeNewswire Inc. - 6/17/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2021 5:20:15 PM
Agenus Announces Virtual Annual Shareholders Meeting GlobeNewswire Inc. - 6/15/2021 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2021 7:54:25 PM
Agenus’ Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN23... GlobeNewswire Inc. - 6/4/2021 9:09:17 AM
Agenus to Participate in Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference GlobeNewswire Inc. - 6/1/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/21/2021 6:14:21 PM
Agenus’ anti-PD-1 antibody shows activity in both PD-L1 positive and PD-L1 negative tumors Seeking Alpha - 5/20/2021 8:04:14 AM
Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts GlobeNewswire Inc. - 5/20/2021 7:00:00 AM
Is Agenus Stock Still Worth Buying After Its 20%-Plus Rally? Analyst Weighs In TipRanks - 5/19/2021 4:32:17 PM
dia76ca   Monday, 02/25/19 11:24:24 AM
Re: None
Post # of 1153 
The Facts About PD-1 according to Feb.25 newsletter. Most of the newsletter explains the innovative BEST financing method.

• Commercial opportunity for our PD-1 in 2L cervical cancer represents up to ~$300M in estimated annual US sales for Agenus
• Commercial opportunity in expanded indications and/or combinations1 represent up to ~$1.5-2Bn in potential annual US sales
for Agenus
• Our PD-1 (AGEN2034) is on track for a BLA filing in 2020 for treatment of 2nd line cervical cancer
• Agenus’ operating plans for approval in cervical cancer are supported by our current budget; Exploiting the market beyond
cervical cancer will require additional investment

• All PD-1 antibodies that have entered late-stage clinical development have been approved; our PD-1 is in late stage development
• Combinations with PD-1 have shown improved benefit for patients - the field is moving to PD-1 combinations
• Agenus’ deep pipeline enables optimal combinations with our PD-1, including combinations with our next generation CTLA-4
• The large and growing market for approved PD-1s is estimated at ~$20B in 2019

"The refusal of the real is the number one dogma of our time" Rene Girard
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences